ScholarlyCommons
metadata only
DIRECT PHARMACOLOGICAL TARGETING OF MYCN IN NEUROBLASTOMA: MECHANISTIC CHARACTERIZATION AND BIOLOGICAL CONSEQUENCES OF MYC-MAX DISRUPTION
2026
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)#1094045
- Triple-amplified sequential activation allosteric DNA biosensor for in vivo quantitative detection of MYCN copy number in neuroblastoma.#378487
- Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma#838900
- Induction Chemoimmunotherapy for Patients With High-risk Neuroblastoma#888320
- Iodobenzylguanidine Meta-I131 and Topotecan in Young Patients With Refractory or Relapsed Metastatic Neuroblastoma#1007214
Record · ID 929118
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive